I think in the upcoming longhaulers trial they should be a little picky. Those with few symptoms will not differentiate leronlimab as widely from placebo as those that have many. Also inclusion/exclusion should be based partially on the endpoints. For instance if one of the endpoints is a walking test inclusion requires pulmonary problems. This should set the trial up for best possible results.